- This event has passed.
Clinical Implications of Roctavian’s Market Withdrawal
April 7 @ 5:30 pm - 6:30 pm
The recent withdrawal of Roctavian from the market has raised important questions for clinicians, patients, and healthcare systems involved in the management of haemophilia A gene therapy. As the first approved GT medicine for adults with severe haemophilia A, Roctavian represented a significant milestone in the evolution of treatment options, and the effects of its withdrawal remain to be seen. This online session explores the clinical implications of its withdrawal, including considerations for patient management, ongoing monitoring of treated individuals, and the broader impact on the future of gene therapy in haemophilia.
Watch this insightful discussion on what this development means for clinical practice and the haemophilia community.